J Immunother Cancer: Efficacy and safety of immune checkpoint inhibitors in patients with psoriasis

Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancers
.

Retrospective analysis showed that although the disease may worsen, the safety of ICIs for most patients with autoimmune diseases is acceptable

Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancers

In this retrospective cohort study, patients with psoriasis tumors treated with ICI from 8 academic centers were included in the study evaluation
.

The main safety results are exacerbation of psoriasis and immune-related adverse events (irAEs)

In this retrospective cohort study, patients with psoriasis tumors treated with ICI from 8 academic centers were included in the study evaluation

Of the 76 patients, 50 (66%) were male, with a median age of 67 years (range 25-92 years)

Forty-three patients (57%) experienced exacerbation of psoriasis at a median of 44 days after ICI treatment (range 1725 days)

In addition to exacerbation of psoriasis, other irAEs were observed in 45 patients (59%), including grade 3 to 4 irAEs in 17 patients (22%)
.

The observed ratio of anti-PD-1/PD-L1 grade 3-4 irAEs was 16%, ipilimumab was 37.

In addition to exacerbation of psoriasis, other irAEs were observed in 45 patients (59%), including grade 3 to 4 irAEs in 17 patients (22%)

Patients with melanoma (N=62) had a median PFS of 39 months and a median OS of 87 months

Among patients with advanced melanoma, the median PFS of patients with exacerbation of psoriasis was 43.
8 months, and that of patients without exacerbation was 5.
0 months (p=0.
015); the median OS of patients with exacerbation of psoriasis did not reach, while in patients without exacerbation it was 29.
3 Month (p=0.
024)
.

Among patients with advanced melanoma, the median PFS of patients with exacerbation of psoriasis was 43.
8 months, and that of patients without exacerbation was 5.
0 months (p=0.
015); the median OS of patients with exacerbation of psoriasis did not reach, while in patients without exacerbation it was 29.
3 Month (p=0.
024)
.

Among patients with advanced melanoma, the median PFS of patients with exacerbation of psoriasis was 43.

The median progression-free survival (PFS) of patients with irAE was 43.
8 months, and that of patients without irAE was 2.
8 months (p<0.
001); while the median OS of patients with irAE was 87.
3 months and that of patients without irAE was 17.
1 months (p=0.
0006)
.

The median progression-free survival (PFS) of patients with irAE was 43.
8 months, and that of patients without irAE was 2.
8 months (p<0.
001); while the median OS of patients with irAE was 87.
3 months and that of patients without irAE was 17.
1 months (p=0.
0006)
.

The median progression-free survival (PFS) of patients with irAE was 43.

Of all patients, 69 patients had an evaluable response, including 3 patients who received neoadjuvant therapy
.
The remission rate was 52.
1% (23 CR, 13 PR), and the other 9 patients were in stable condition
.
The median PFS was 20.
0 months, and the median OS was 87.
3 months
.
The median PFS of patients with exacerbation of psoriasis was 39 months, and that of patients without exacerbation was 8.
7 months (p=0.
049); the median OS of patients with exacerbation of psoriasis was not reached, and the median OS of patients without exacerbation was 29.
3 months (p=0.
045)
.
Similarly, the median progression-free survival (PFS) of the irAE group was 39.
0 months, and that of the irAE group was 3.
4 months (p=0.
018); the median OS of the irAE group was 87.
3 months, and the median OS of the irAE group was 17.
5 months ( p=0.
028)
.

Of all patients, 69 patients had an evaluable response, including 3 patients who received neoadjuvant therapy
.
The remission rate was 52.
1% (23 CR, 13 PR), and the other 9 patients were in stable condition
.
The median PFS was 20.
0 months, and the median OS was 87.
3 months
.
The median PFS of patients with exacerbation of psoriasis was 39 months, and that of patients without exacerbation was 8.
7 months (p=0.
049); the median OS of patients with exacerbation of psoriasis was not reached, and the median OS of patients without exacerbation was 29.
3 months (p=0.
045)
.
Similarly, the median progression-free survival (PFS) of the irAE group was 39.
0 months, and that of the irAE group was 3.
4 months (p=0.
018); the median OS of the irAE group was 87.
3 months, and the median OS of the irAE group was 17.
5 months ( p=0.
028)
.
Of all patients, 69 patients had an evaluable response, including 3 patients who received neoadjuvant therapy
.
The remission rate was 52.
1% (23 CR, 13 PR), and the other 9 patients were in stable condition
.
The median PFS was 20.
0 months, and the median OS was 87.
3 months
.
The median PFS of patients with exacerbation of psoriasis was 39 months, and that of patients without exacerbation was 8.
7 months (p=0.
049); the median OS of patients with exacerbation of psoriasis was not reached, and the median OS of patients without exacerbation was 29.
3 months (p=0.
045)
.
Similarly, the median progression-free survival (PFS) of the irAE group was 39.
0 months, and that of the irAE group was 3.
4 months (p=0.
018); the median OS of the irAE group was 87.
3 months, and the median OS of the irAE group was 17.
5 months ( p=0.
028)
.

In summary, the study shows that most of the treatments with immune checkpoint inhibitors (ICIs) can lead to exacerbation of psoriasis, but they are controllable and rarely need to be discontinued
.
And worsening psoriasis will not weaken the efficacy of ICIs
.
Therefore, patients with psoriasis can also treat tumors with ICIs
.

In summary, the study shows that most of the treatments with immune checkpoint inhibitors (ICIs) can lead to exacerbation of psoriasis, but they are controllable and rarely need to be discontinued
.
And worsening psoriasis will not weaken the efficacy of ICIs
.
Therefore, patients with psoriasis can also treat tumors with ICIs
.
The study showed that most treatments with immune checkpoint inhibitors (ICIs) can cause psoriasis to worsen, but they are manageable and rarely need to be discontinued
.
And worsening psoriasis will not weaken the efficacy of ICIs
.
Therefore, patients with psoriasis can also treat tumors with ICIs
.
The study showed that most treatments with immune checkpoint inhibitors (ICIs) can cause psoriasis to worsen, but they are manageable and rarely need to be discontinued
.
And worsening psoriasis will not weaken the efficacy of ICIs
.
Therefore, patients with psoriasis can also treat tumors with ICIs
.

Original source:

Original source:

Halle BR, Betof Warner A, Zaman FY, et al.
Immune checkpoint inhibitors in patients with pre- existin psoriasis: safety and efficacy.
Journal for Immuno Therapy of Cancer 2021;9:e003066.
doi:10.
1136/jitc-2021-003066

.
Halle BR, Betof Warner A, Zaman FY, et al Immune checkpoint inhibitors in patients with pre- existin psoriasis: safety and efficacy.
Journal for Immuno Therapy of Cancer 2021; 9: e003066.
doi: 10.
1136 / jitc-2021-003066 in This message